Navigation Links
Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
Date:3/28/2008

TOKYO and WOODCLIFF LAKE, N.J., March 28 /PRNewswire/ -- Eisai Co., Ltd. and its U.S. subsidiary Eisai Inc. (collectively "Eisai") today announced that the United States District Court for the District of New Jersey has ruled in Eisai's favor with respect to Eisai's motion for a preliminary injunction in its patent infringement lawsuit against Teva Pharmaceuticals and its division Gate Pharmaceuticals (collectively "Teva"), concerning Aricept(R) (generic name: donepezil hydrochloride tablets).

As previously announced, Eisai filed the infringement actions in December 2005 contesting Teva's submission of an abbreviated new drug application (ANDA) to the FDA for Aricept(R).

"We are pleased with the court's preliminary injunction decision to prevent the sale of Teva's generic product before the expiration of the donepezil composition of matter patent," said Mr. Hajime Shimizu, Chairman & CEO of Eisai Corporation of North America and Eisai Inc. "We will continue to actively protect our intellectual property throughout the world."

Aricept(R), an acetylcholinesterase inhibitor developed by Eisai Co., Ltd. in Japan, increases the concentration of acetylcholine, a neurotransmitter, in the brain. Aricept(R) was launched in the United States in 1997 and is indicated for the treatment of mild, moderate, and severe dementia of the Alzheimer's type. In the United States, Eisai Inc. copromotes Aricept(R) with Pfizer Inc.

About Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai's corporate human health care (hhc) mission is to give first thought to patients and their families, and to increase the benefits that health care provides. The company believes that increasing patient satisfaction through the development of innovative new medicines exemplifies its important mission. For more information about Eisai Co., Ltd., please visit '/>"/>

SOURCE Eisai Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Eisai/Pfizers Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimers Disease
2. Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
3. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
4. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
5. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
6. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
7. Kiwa Bio-Tech New Bio-Fertilizer Product Granted Initial Fertilizer Registration Certificate By Ministry of Agriculture of the PRC
8. Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis
9. Odyssey Thera Granted U.S. Patent for Animal Imaging
10. ISTO Technologies Granted Key Patent for Cartilage Cell Expansion by the United States Patent Office
11. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., ... has filed a Clinical Trial Application (CTA) with the ... Regulatory Agency (MHRA) seeking regulatory approval to initiate clinical ... Anatabine Citrate. Contingent on the Company receiving ... Phase I trial to assess the safety, tolerability and ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... , Dec. 22, 2014 GenomeDx Biosciences ... Decipher Prostate Cancer Classifier, a genomic test for prostate ... node-negative, high-risk men managed by radical prostatectomy without adjuvant ... prostatectomy is relatively uncommon, using tumor genomics to identify ... metastatic disease is an important advance. The study has ...
(Date:12/22/2014)... 22, 2014 ITRA Global, one of ... of commercial real estate, has further expanded its global ... Perth and Brisbane, Western Australia, reports Mylinda Vick, CCIM, ... ITRA Global / ACORPP (Australian Corporate Property and ... company providing property services to a wide range of ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... and more. MADISON, Wis. My UW Madison ... and faculty for online organizational and scheduling tasksis migrating ... the project, Arizona-based Unicon, was also announced. , ,The ... be complete by August 2005. According to Brian Rust, ...
... Simon, left, and Charletta D. Flowers, right, who work for ... works for the Energizer Battery Company in St. Louis. ... of Milwaukee (YPM) threw an elaborate party at Milwaukee's ... ,The group had a lot to be proud of. In ...
... Islands in the Clickstream ... digital world. WTN will be reprinting excerpts from selected chapters of ... features an excerpt from chapter six, Mostly True Predictions. We hope ... A Vision of Possibilities , ,By Richard Thieme , ,It ...
Cached Biology Technology:"My UW Madison" portal migrating to uPortal 2Young Professionals of Milwaukee Celebrates Its Third Birthday, Looks To The Future 2Young Professionals of Milwaukee Celebrates Its Third Birthday, Looks To The Future 3Islands in the Clickstream: A Vision of Possibilities 2Islands in the Clickstream: A Vision of Possibilities 3Islands in the Clickstream: A Vision of Possibilities 4
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... a case of life imitating art, avian scents given off ... A Michigan State University researcher revealed the process of ... the current issue of Behavioral Ecology . Scents are ... attracting and evaluating mates. But this is the first study ...
... How is it that a disc-like cluster of cells transforms ... This mechanism is a mystery that man has tried ... towards understanding the issue was made nearly a century ago ... Hilde Mangold. The two used early newt embryos and identified ...
... expanded use of electronic health records (EHRs) to address ... system that can lead to readmissions and even death. ... JAMA , The Journal of the American ... using electronic health records to address patient safety issues," ...
Cached Biology News:Avian 'Axe effect' attracts attention of females and males 2Hebrew U. scientists show for first time how early human embryo acquires its shape 2E-health records should play bigger role in patient safety initiatives, researchers advocate 2
... The IDS Corticosterone kit is a ... of corticosterone in mouse or rat serum ... not sole, corticosteroid in rats and mice, ... amphibia, birds and reptiles. Most mammals produce ...
Mouse monoclonal [BC-4] to Aggrecan xxPEN ( Abpromise for all tested applications). entrezGeneID: 176 SwissProtID: P16112...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
7G10 anti-Fasciclin III...
Biology Products: